Drug Profile
Eculizumab biosimilar - CinnaGen
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CinnaGen
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 19 Mar 2021 No development reported - Phase-II/III for Paroxysmal nocturnal haemoglobinuria in Iran (Parenteral)